Remed Co

Remed Co Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Remed Co (302550.KQ) as of Nov 19, 2026 is 219.14. In the previous year, Cash Conversion Cycle (CCC) was 287.98 — a change of -23.91% (lower).

Cash Conversion Cycle

219.14

YoY

-23.91%

Last updated:

Cash Conversion Cycle (CCC) of Remed Co is 2025 219.14 . Cash Conversion Cycle (CCC) of Remed Co was 2024 287.98 . It decreases by -23.91% lower compared to the previous year.

The Remed Co Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
239.73 KRW
Jan 1, 2019
163.04 KRW
Jan 1, 2020
175.85 KRW
Jan 1, 2021
270.47 KRW
Jan 1, 2022
261.66 KRW
Jan 1, 2023
273.81 KRW
Jan 1, 2024
287.98 KRW
Jan 1, 2025
219.14 KRW
The Remed Co Cash Conversion Cycle history
YEARCash Conversion CycleYoY
219.14-23.91%
287.98+5.18%
273.81+4.65%
261.66-3.26%
270.47+53.81%
175.85+7.86%
163.04-31.99%
239.73+0.42%
238.72—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Remed Co Stock analysis

What does Remed Co do? REMED Co., Ltd. generates revenue through the manufacturing and sale of medical equipment, including transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, and biosignal and monitoring machines. Pain therapy machines encompass electromagnetic stimulation machines, extracorporeal shockwave therapy machines, and high intensity laser therapy machines. Biosignal and monitoring machines include patient monitors, fetal monitors, and electrocardiogram (ECG/EKG) machines. The company distributes these products domestically and internationally, targeting healthcare providers and medical facilities that require specialized therapeutic and monitoring solutions. The firm's product portfolio focuses on advanced medical devices for neurological and pain management, as well as patient monitoring. Transcranial magnetic stimulation (TMS) therapy machines are used for neurological treatments, while pain therapy machines address chronic pain conditions. Biosignal and monitoring machines support critical patient care, with electrocardiogram (ECG/EKG) machines being a key component. These products are sold to hospitals, clinics, and medical centers across domestic and overseas markets. REMED Co., Ltd. serves healthcare institutions that require specialized equipment for diagnosis, treatment, and monitoring. The domestic market includes hospitals and clinics in Daejeon, while overseas markets extend to international healthcare providers. The company’s revenue streams are derived from direct sales of its medical equipment, with no mention of additional services or licensing agreements in the business description. Remed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Remed Co stock

Cash Conversion Cycle (CCC) of Remed Co is 219.14 in 2025.

Cash Conversion Cycle (CCC) of Remed Co changed from 287.98 to 219.14, representing a -23.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Remed Co since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Remed Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Remed Co

All Key Metrics — Remed Co